Biogen (NASDAQ:BIIB) Releases FY24 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $16.10-16.60 for the period, compared to the consensus EPS estimate of $16.17. Biogen also updated its FY 2024 guidance to 16.100-16.600 EPS.

Biogen Price Performance

Shares of BIIB traded down $0.21 during midday trading on Friday, hitting $173.79. The company’s stock had a trading volume of 1,456,042 shares, compared to its average volume of 1,134,143. Biogen has a one year low of $173.14 and a one year high of $268.30. The company has a quick ratio of 1.48, a current ratio of 1.26 and a debt-to-equity ratio of 0.28. The company’s fifty day simple moving average is $192.71 and its two-hundred day simple moving average is $209.37. The stock has a market capitalization of $25.31 billion, a price-to-earnings ratio of 15.70, a price-to-earnings-growth ratio of 1.82 and a beta of -0.06.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.31. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The company had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.43 billion. During the same quarter in the previous year, the firm posted $4.36 earnings per share. Biogen’s revenue for the quarter was down 2.5% on a year-over-year basis. As a group, equities analysts expect that Biogen will post 16.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BIIB has been the subject of several recent analyst reports. Piper Sandler decreased their target price on Biogen from $335.00 to $313.00 and set an “overweight” rating for the company in a research note on Friday, July 12th. Morgan Stanley lowered shares of Biogen from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $285.00 to $204.00 in a research note on Thursday. Mizuho cut their target price on shares of Biogen from $277.00 to $251.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $270.00 price target on shares of Biogen in a report on Wednesday. Finally, StockNews.com upgraded shares of Biogen from a “buy” rating to a “strong-buy” rating in a report on Monday, September 2nd. Ten analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $262.83.

Insider Activity at Biogen

In other Biogen news, insider Priya Singhal sold 431 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $204.22, for a total transaction of $88,018.82. Following the transaction, the insider now directly owns 5,316 shares in the company, valued at $1,085,633.52. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.